Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Culmerciclib + letrozole + trastuzumab + pertuzumab neoadjuvant phase II study in HR-positive/HER2-positive breast cancer
ChiCTR2600131713Phase 2Not yet recruiting
- Sponsor
- Weihai Municipal Hospital
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of culmerciclib, letrozole, trastuzumab and pertuzumab in breast cancer, sponsored by Weihai Municipal Hospital. Primary endpoint: Overall pathological complete response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600131713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131713.